OncoCheck NGS Panel

Overview

OncoCheck NGS assay is aimed to screen a range of disease causing genes to identify somatic mutations and germline mutations in DNA from FFPE, fresh tissue, and blood targeting 53 genes covering all the coding sequences enriched by hybridization capture-based target enrichment methodology. Genes are selected based on AMP/ASCO/CAP guidelines to uncover the coding region compiling to the size of 0.17 Mb.

Key Features & Highlights

  • Comprehensive Gene Coverage: Targets 53 clinically relevant genes associated with somatic and germline mutations, ensuring broad disease screening.
  • Full Coding Region Analysis: Covers entire coding sequences (0.17 Mb) for accurate mutation detection and interpretation.
  • Advanced Enrichment Technology: Utilizes hybridization capture-based target enrichment for superior specificity and uniform coverage.
  • Multi-Sample Compatibility: Designed for DNA from FFPE tissue, fresh tissue, and blood, enabling flexibility in sample types.
  • Guideline-Driven Gene Selection: Genes curated based on AMP/ASCO/CAP recommendations for clinically actionable insights.

Panel Specifications

Parameter
Description
No. of genes:
53
Variant types:
SNVs/ Indels/ CNVs
Covered region:
Whole CDS
Target Size:
0.17 Mb
Coverage recommendations:
Germline (Blood): 180X
Somatic (Solid Tumor): 2000X
Data requirement (per sample:
Germline: 50 Mb
Somatic: 334 Mb
Sample Type:
Blood / FFPE
Recommended sample (input range):
DNA: 50-500 ng
Workflow time:
~1.5 Day
Platform Compatibility:
Illumina, MGI, Thermo Fisher, Element Biosciences
Bioinformatics Support:
G2M CliSeq Interpreter
Primary Analysis: FASTQ to annotated VCF
Secondary Analysis: CNVs, SNVs, InDel, Fusions
Tertiary Analysis: Clinical interpretation

Panel Performance

Features
Performance
Coverage Uniformity (0.2X):
>99%
Reproducibility (%):
97.9
Sensitivity (%):
96.7
On Target Ratio (%):
75-85

Precision Enrichment Delivering Superior On-Target Performance

Melting Curve

On-target ratio performance of the OncoCheck NGS Assay across samples maintains a high on-target alignment (ranging from 76.0% to 79.5%), reflecting exceptional assay design, optimized enrichment, and reliable sequencing accuracy for comprehensive genomic profiling.

Unwavering Uniformity in OncoCheck Assay Performance

Allelic Discrimination Plot

Uniformity of OncoCheck NGS Assay coverage across samples consistently achieves 100% coverage at 0.2X depth, demonstrating exceptional assay design and reproducibility for reliable genomic analysis.

Ordering Information

Commercial Name Old Cat No. New Cat No. Pack Size Platform
OncoCheck NGS Test Kit (HRR) G2MOC01001 G710002-1 24 T Illumina
G2MOC01001 G710002-2 96 T Illumina
G2MOC01001 G710002-3 96 T – EZY Illumina – EZY
OncoCheck NGS Test Kit (HRR) G2MOC01001 G710002-4 24 T MGI
G2MOC01001 G710002-5 96 T MGI
G2MOC01001 G710002-6 96 T – EZY MGI – EZY
OncoCheck NGS Test Kit (HRR) G2MOC01001 G710002-7 24 T Aviti
G2MOC01001 G710002-8 96 T Aviti
G2MOC01001 G710002-9 96 T – EZY Aviti – EZY
OncoCheck NGS Test Kit (HRR) G2MOC01001 G710002-10 24 T Thermo
G2MOC01001 G710002-11 96 T Thermo
G2MOC01001 G710002-12 96 T – EZY Thermo – EZY

Product Enquiry Form

Other Products

Rapi-Q
RapiX-16

Automated Nucleic Acid Extraction System.

Rapi Cycler
Ezy-Autoprep-48

Automatic NGS Library Preparation Workstation.

CliSeq-Interpreter
CliSeq Interpreter

CliSeq Interpreter by Genes2Me is a cloud-based.

Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.

© 2025 Genes2me. All rights reserved.